This presentation examines the Inflation Reduction Act (IRA) and its quantitative impact on retail pharmacies, with a focus on drug price negotiations, Maximum Fair Prices (MFPs), and resulting cash-flow and working-capital pressures. Leveraging Inmar Intelligence data across 35 pharmacy chains, it illustrates how IRA-designated drugs will represent a growing share of sales while extending receivable timelines and increasing operational complexity. The presentation also includes an overview on the Drug Supply Chain Security Act (DSCSA), summarizing the impact to date on dispensers, including interoperability readiness, exception handling, and ongoing compliance challenges since the November 27, 2025 final milestone. Together, these dynamics highlight the need for pharmacies to strengthen financial, operational, and compliance strategies while continuing to support patient access and affordability under evolving federal regulations.